# Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

> **NCT02274233** · PHASE1 · TERMINATED · sponsor: **Sideris Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Iron Overload
- Beta-Thalassemia

## Interventions

- **DRUG:** SP-420

## Key facts

- **NCT ID:** NCT02274233
- **Lead sponsor:** Sideris Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Changes in renal function parameters.
- **Last updated:** 2015-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02274233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02274233, "Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02274233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*